Share:NEW YORK — AstraZeneca PLC has made a preliminary approach to rival drug maker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health care deal on record. The UK company informally contacted Gilead last month to gauge its interest in a possible tie-up, […]
Share:Last week, Novartis was touting positive data showing its repurposed leukemia drug ofatumumab outpaced Sanofi’s Aubagio in a multiple sclerosis trial. Now, Novartis has revealed that the FDA, which was supposed to hand down a verdict on the drug this month, needs until September to make the decision. What happened? Novartis isn’t saying much. MORE… […]
Share:The primary sources employed while generating this Diabetic Retinopathy Treatment Market report include the industry experts from the industry comprising the management corporation, processing organizations, analytical service suppliers of the industry’s value chain. All primary sources are interviewed to accumulate the data and validate qualitative & quantitative information and conclude future prospects. Secondary research consists […]
Share: Rapid and profound depletion of B-cells contributed to a halt in disease activity in RMS patients1 A post hoc analysis showed 47.0% and 87.8% of patients treated with ofatumumab achieved no evidence of disease activity (NEDA-3) within the first (0–12 months) and second year (12–24 months) of treatment, respectively1 Regulatory action for ofatumumab in […]
Share:Gilead will increase the number of doses of remdesivir it’s donating to the federal government in the next six weeks, STAT reported. The drugmaker had planned to donate 607,000 vials of remdesivir — the drug that received FDA emergency approval for use in treating COVID-19 patients after it was shown to shorten recovery time in patients with the virus […]
Share:NurOwn, a cell-based therapy that protects and helps repair nerve cells, also may be able to curb the damaging brain inflammation that contributes to the progression of amyotrophic lateral sclerosis (ALS), recent findings suggest. Researchers believe this newly-found potential may extend the benefits of NurOwn in ALS patients and possibly among those with other conditions. […]
Share:BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is currently conducting a Phase 3 clinical trial of NurOwn® in patients with amyotrophic lateral sclerosis (ALS) (NCT03280056). A total of 200 patients were randomized 1:1 to receive NurOwn® or placebo in the randomized, double blind, placebo controlled, multi-dose trial. Cells were extracted once from each patient prior to treatment, […]
Share:Within a week of the Food and Drug Administration’s authorization of remdesivir as a COVID-19 treatment, clinicians are pushing the Trump administration to clarify how it is selecting which hospitals get access to the drug. Shares of Gilead Sciences Inc. GILD, +0.18%, which developed remdesivir, edged up 0.2% in Thursday trades and are up 19.4% in 2020. MORE…
Share:As COVID-19 ravages across the globe, Regeneron has responded with its own two-pronged approach against the disease. After early results in China showed inhibiting IL-6 could manage a potentially deadly immune overreaction in serious COVID-19 patients, Regeneron and partner Sanofi started a phase 2/3 trial of their rheumatoid arthritis therapy Kevzara, following a similar move […]
Share:Compass Pathways has raised $80 million to prepare its psilocybin therapy for phase 3 development. The London-based biotech is advancing the drug, the active ingredient in magic mushrooms, for use in people with treatment-resistant depression. Psilocybin was studied in the 1960s, but research ground to a halt over the following decades. Teams at academic centers including the […]